Alliance for Regenerative Medicine: Decoding the 2026 Data

Introduction: Why ARM’s 2026 Numbers Matter Right Now

The Alliance for Regenerative Medicine (ARM) is often described as an advocacy group, but for anyone trying to understand cell and gene therapy (CGT), its more important role is as the sector’s primary data clearinghouse. When trade reporters, market analysts, and policymakers need a baseline figure for investment, clinical activity, or regulatory outcomes, they usually start with ARM.

In 2026, four data points stand out:

1. The January 2026 State of the Industry (SOTI) briefing, which declared that the sector has entered a “disciplined, sustainable growth cycle.”
2. Five commercial CGT blockbusters, the clearest evidence yet that these therapies have become commercial products.
3. A jump in FDA Complete Response Letters (CRLs) for new CGT decisions, from 18% to 42%.
4. More than a decade of financing swings, which show how sensitive the sector remains to capital markets.

This article explains how to use these metrics in practice: to evaluate investment risk, to verify claims in reporting, or to gauge where a specific therapy might stand on the path to approval. Two illustrative, anonymized pipeline types common among long-standing ARM participants serve as running examples to make the sector-level data concrete.

ARM’s Role as the Sector’s Data Authority

ARM is a nonprofit headquartered in Washington, D.C., founded in 2009. It represents more than 400 member institutions (some sources cite 425) across 25 countries and is led by CEO Tim Hunt. Its membership includes emerging and established biotechnology companies, academic and medical research institutions, patient organizations, and strategic suppliers.

That breadth explains much of ARM’s authority as a data source. The organization aggregates financing, clinical-trial, and regulatory data across the full CGT ecosystem rather than a single slice of it. A figure drawn from ARM reflects developers, research centers, and suppliers together, which makes it more representative than a tally built from a single company type or region.

Just as important, ARM publishes recurring, dated data products:

• The annual SOTI briefing, delivered each January during the week of the J.P. Morgan Healthcare Conference in San Francisco.
• Quarterly Sector Snapshots, which update investment, clinical, and regulatory figures throughout the year.

Because these products follow a consistent schedule and methodology, ARM’s numbers can be tracked over time rather than treated as one-off estimates. That consistency is why trade outlets such as BioWorld and FierceBiotech, along with market-research reports and policy analysts, routinely cite ARM figures as a baseline.

Inside the January 2026 State of the Industry Briefing

At the January 2026 SOTI briefing, Tim Hunt’s central message was optimistic but measured. After several lean years of learning, adapting, and absorbing setbacks, he said, the CGT sector is now self-sustaining and has entered a “disciplined, sustainable growth cycle.”

In practice, “disciplined growth” points to a different capital environment than in earlier years. Investors are making fewer speculative bets on early science and concentrating money in de-risked, later-stage programs with clearer clinical and commercial paths. The sector is growing, but more selectively.

The ‘Disciplined, Sustainable Growth Cycle’ Explained

CGT has gone through several boom-and-bust phases. Financing surged in 2018, reached pandemic-era highs in 2020 and 2021, and then pulled back sharply as interest rates rose and investor risk appetite declined. Each cycle brought a wave of new companies, followed by consolidation and layoffs.

The 2026 framing describes a steadier trajectory. ARM’s Q4 2025 Sector Snapshot supports that view, tracking 1,943+ active clinical trials and developers globally and roughly $3.2 billion in quarterly sector investment across major regions. Neither figure suggests a speculative frenzy. Taken together, they describe a large, active pipeline funded at a sustainable pace.

Rising Competitive Pressure from China

Hunt also flagged mounting competition from China as a factor to watch. China’s CGT development capacity has expanded quickly, and its developers are increasingly competitive on trial speed and cost. For investors, this affects which programs may be first to market. For policymakers, it raises questions about how regulatory and reimbursement frameworks in the U.S. and Europe affect where innovation happens.

ARM’s international footprint gives it an advantage on this topic. With members in 25 countries, it can compare development activity across regions in a way that U.S.-centric data sources cannot.

The Five Commercial Blockbusters Defining the Sector

ARM counts five commercial CGT blockbusters as of 2025, based on annual sales:

Therapy	2025 Sales	Notable Growth
Carvykti	$1.9B	Up 97%
Yescarta	$1.5B	Established CAR-T leader
Breyanzi	$1.3B	Up 82%
Zolgensma	$1.2B	Gene therapy for spinal muscular atrophy
Elevidys	~$898.7M	Gene therapy for Duchenne muscular dystrophy

ARM treats this group as proof that CGT has moved from experimental promise to commercial reality. A decade ago, critics questioned whether complex, individualized therapies could ever be manufactured, reimbursed, and delivered at scale. Five products at or near blockbuster status, across both cell and gene therapy categories, offer a direct answer.

Reading the Growth Rates: Carvykti and Breyanzi as Signals

The growth rates may matter more than the totals. Carvykti’s 97% increase and Breyanzi’s 82% increase mean these CAR-T therapies nearly doubled their sales in a single year. That rate of growth usually reflects more treatment centers, wider payer acceptance, and use in earlier lines of therapy.

The growth also connects to ARM’s policy work. ARM helped secure a dedicated diagnosis-related group (DRG) for CAR-T reimbursement in the U.S., which reduced the financial burden on hospitals administering these therapies. When reimbursement barriers come down, uptake tends to follow, and the CAR-T sales figures illustrate that link between a policy win and commercial results.

The Path to 10 Blockbusters by 2031

ARM forecasts up to 10 CGT blockbusters by 2031. Reaching that number would require several conditions to hold at once:

• Late-stage programs would need to convert to approvals at a healthy rate, despite the higher CRL environment.
• Manufacturing capacity would need to scale without bottlenecks.
• Payers would need to keep extending coverage, including for larger patient populations.

The forecast also gives investors and journalists a useful benchmark. Each year’s blockbuster count can be compared with ARM’s own projection to show whether the sector is ahead of, on, or behind schedule.

The Regulatory Storm: Complete Response Letters Climb from 18% to 42%

The most consequential number in the 2026 data set may be this one: ARM reports that the share of FDA/CBER new CGT decisions ending in a Complete Response Letter has risen from 18% to 42%.

A CRL means the FDA will not approve an application in its current form. With roughly two in five new decisions now ending this way, regulatory risk has become a major swing variable for the sector. Strong clinical data no longer guarantees a smooth approval, and a single CRL can delay a launch by a year or more.

What’s Driving the CRL Surge

Several factors likely contribute:

• Closer scrutiny of manufacturing and CMC data. Cell and gene therapies are hard to characterize and reproduce consistently. Chemistry, manufacturing, and controls (CMC) packages draw intense review.
• A higher bar for accelerated approval. Regulators are asking for stronger evidence linking surrogate endpoints to clinical benefit.
• More novel, first-in-class submissions. As the pipeline matures, more applications involve new modalities without established regulatory precedent.

ARM has worked on this issue directly. Its advocacy helped secure increased FDA staffing for CGT reviewers, along with language in the PDUFA VII agreement that promotes CMC clarity and greater use of real-world evidence. Those efforts are aimed at making regulatory expectations more predictable, which addresses one of the main causes of CRLs.

A Counterpoint: KRESLADI’s Accelerated Approval

The higher CRL rate does not mean the approval pathway is closed. On March 26, 2026, the FDA granted accelerated approval to Rocket Pharmaceuticals’ KRESLADI for severe leukocyte adhesion deficiency-I. It was the first U.S. gene therapy approval of 2026, and ARM highlighted it in its Q1 2026 Sector Snapshot.

KRESLADI shows that approvals are still happening. What has changed is the margin for error. Preparation, data quality, and manufacturing readiness now matter more than they did a few years ago.

Financing Swings: Reading ARM’s Historic Investment Data

ARM’s longitudinal financing data show how volatile the sector has been:

• 2013-2014: $4.7 billion in combined deal value.
• 2018: $13.5 billion, a 73% increase over 2017.
• Through Q3 2020: A pandemic-era record of $15.9 billion in just three quarters.
• H1 2021: $14.1 billion in six months, equal to 71% of all 2020 financing.

The sector’s capital base grew several times over in less than a decade, then contracted sharply. These swings track broader market conditions: low interest rates and high investor enthusiasm pushed money into CGT, and tighter monetary conditions pulled it back out. For capital-intensive companies with long development timelines, those cycles can determine whether a promising program survives.

The 2024-2026 Recovery Signal

After what Tim Hunt called a “very challenging” two-to-three-year stretch, the data turned. Hunt reported $10.9 billion in CGT investment in the first half of 2024, more than all of 2019’s $9.8 billion.

That recovery supports the January 2026 “disciplined growth” message. Funding did not return to the extremes of 2020-2021. It settled at a sustainable level that remains well above pre-pandemic norms, which is consistent with the growth cycle Hunt now describes.

From Data to Decisions: What the Numbers Mean for Investors

ARM’s data suggest a practical framework for investors:

• Favor de-risked assets. The blockbuster data show where commercial value is being realized. Platforms with commercial-stage products or near-term regulatory catalysts fit the disciplined-growth environment better than purely early-stage science.
• Weight regulatory readiness heavily. With CRL rates at 42%, CMC maturity and the history of a company’s interactions with the FDA deserve as much attention as efficacy data. A strong trial readout does not protect against manufacturing deficiencies.
• Use quarterly benchmarks. ARM’s Sector Snapshot investment totals, such as the roughly $3.2 billion per quarter reported in Q4 2025, give a reference point for judging whether a financing round or regional trend is above or below sector norms.

What the Numbers Mean for Journalists Citing ARM

Accurate attribution matters because ARM figures are reused so widely. A few rules apply:

• Specify the reporting period. An annual SOTI figure and a quarterly Sector Snapshot figure can differ substantially. “ARM reported” is incomplete without the date and the specific publication.
• Go to the primary source. The SOTI presentation and Sector Snapshot documents are published directly by ARM. Secondary trade-press summaries sometimes round, combine, or misdate figures.
• Recognize ARM’s role as a reference point. BioWorld, FierceBiotech, and many market-research reports anchor their analysis to ARM data. An error in attribution can spread quickly across outlets, so precision benefits the wider information ecosystem.

What the Numbers Mean for Patients Tracking a Specific Therapy

For patients and caregivers, the regulatory data need plain-language context. A rising CRL rate does not predict the outcome for any single therapy. It does mean that timelines may stretch, resubmissions are increasingly common, and an initial rejection is not necessarily the end of a program.

Approval is also only one step toward access. ARM’s newborn screening advocacy illustrates this. In 2025, ARM wrote to the House Energy & Commerce Committee in support of the Newborn Screening Saves Lives Reauthorization Act. It cited savings of roughly $168,000 to $517,000 per case when early diagnosis allows timely access to cell or gene therapy. Earlier diagnosis helps close the gap between a therapy’s approval and the moment a patient can actually receive it.

Patients can also use ARM’s Sector Snapshot approval trackers, such as the KRESLADI milestone, to see where a therapy of interest stands relative to recent approvals in similar disease areas or treatment categories.

Case Studies: Reading ARM’s Metrics Through Illustrative Pipelines

Among ARM’s member community, two broad categories of long-standing participants illustrate how sector-level metrics apply to real pipelines: developers of off-the-shelf, induced pluripotent stem cell (iPSC)-derived therapies, and developers of mesenchymal stromal cell (MSC) therapies. Both categories are well represented at ARM’s Investor Day and the Cell & Gene Meeting on the Mesa.

Reading Pipeline Risk Through the CRL Lens: An iPSC-Derived Therapy Example

Consider a company developing off-the-shelf cell therapies derived from induced pluripotent stem cells. This approach aims to remove the patient-specific manufacturing that makes autologous CAR-T therapies complex and slow to produce. It also introduces new manufacturing questions that regulators have limited precedent for evaluating.

The rise in CRLs from 18% to 42% raises the standard for programs like these. Novel cell therapy submissions now face detailed scrutiny of manufacturing consistency, potency assays, and product characterization. Investors and journalists can apply this sector-wide data point without speculating about confidential details. The useful questions are how mature a company’s CMC processes appear in public disclosures, how often it discusses regulatory alignment, and how its timelines compare with recent approvals and rejections across the sector.

A Case Study in Financing Cycles and Commercial Breakthroughs

A different pattern shows up among MSC-therapy developers, whose histories closely follow the financing cycles ARM has tracked. Companies in this category have, in some cases, spent years developing mesenchymal stromal cell therapies through lean funding periods, received CRLs along the way, and kept working with regulators. In December 2024, the FDA approved the first mesenchymal stromal cell therapy in the United States, for pediatric steroid-refractory acute graft-versus-host disease.

That path mirrors the broader narrative Tim Hunt described in January 2026: years of learning, adapting, and recovering from setbacks, followed by commercial results. This type of trajectory also shows that a CRL can delay a therapy without ending it, which is a useful perspective given the current 42% figure.

How to Access and Verify ARM’s Data Directly

Readers who want to work with ARM’s data directly can follow a simple approach:

• Primary publications: The SOTI briefing (released each January during J.P. Morgan Healthcare Conference week), quarterly Sector Snapshots, and annual reports are published on ARM’s official website, alliancerm.org.
• Flagship events: The Cell & Gene Meeting on the Mesa (held October 5-7, 2026, at the Arizona Biltmore in Phoenix) and the Cell & Gene Meeting on the Med (Rome, April 2026) bring together executives, investors, regulators, and scientists. Updated data are often previewed or discussed at these meetings, along with topics such as trial design, payment models, and manufacturing scale-up.
• Committee structure: ARM’s seven standing committees vet and contextualize much of this data before it is released: Capital Formation, Communications & Education, Government Relations, Regulatory, Reimbursement, Science & Technology, and the Patient Advocacy Coordinating Committee.

Conclusion: Turning ARM’s Numbers Into Informed Decisions

The 2026 data form a connected picture. The “disciplined growth” narrative describes a sector that has matured. The five blockbusters show that CGT can succeed commercially. The CRL surge shows that regulatory risk remains high. The financing history shows how quickly conditions can change.

ARM’s value comes from its consistency. Because it tracks the same metrics on a regular schedule, investors, journalists, and patients can compare new developments against a credible historical baseline instead of reacting to isolated headlines.

The illustrative pipeline examples above show that these figures are not abstract. Each percentage point in the CRL rate and each financing swing affects real pipelines, real companies, and patients waiting for treatment.

Stay Ahead of the Next ARM Data Release

The CGT sector changes from quarter to quarter, so readers should track ARM’s publication schedule. The quarterly Sector Snapshots and the January SOTI briefing are the most important releases. The next SOTI briefing, expected in January 2027, will show whether the disciplined growth cycle has held.

Investors, journalists, and patient advocates can return to this analysis after each new release to check whether the CRL trend is continuing, reversing, or accelerating, and whether the blockbuster count is on track for ARM’s 2031 forecast. Coverage of this month’s Cell & Gene Meeting on the Mesa in Phoenix is also worth following for discussion of these metrics. For readers who follow the medical and life-sciences field through industry resources such as adiamed.com, ARM’s data offer a reliable reference point for interpreting where cell and gene therapy is heading.